Discover

PFS
Provident Financial Services, Inc.
22.09
300 x 22.06
500 x 22.07
bid
ask
-
0.13
0.59%
400 @ 04:00 PM
22.09 +0.00 (0.00%)
Ytd11.85%
1y14.87%
22.01
day range
22.15
17.77
52 week range
25.28
Open22.12Prev Close22.22Low22.01High22.15Mkt Cap2.88B
Vol472.65KAvg Vol900.38KEPS2.40P/E9.20Forward P/E8.55
Beta0.82Short Ratio8.38Inst. Own77.60%Dividend0.96Div Yield4.32
Ex Div Date08-14Earning10-2850-d Avg23.52200-d Avg22.441yr Est27.75

PFS News

New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
gurufocus.com
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists

[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, t

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell
gurufocus.com
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improveme

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improveme

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell
gurufocus.com
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Signifi

[url="]Genmab A/S[/url](Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline resul

Provident Financial Services (NYSE:PFS) vs. Popular (NASDAQ:BPOP) Critical Comparison
defenseworld.net
Provident Financial Services (NYSE:PFS) vs. Popular (NASDAQ:BPOP) Critical Comparison

Popular (NASDAQ: BPOP - Get Free Report) and Provident Financial Services (NYSE: PFS - Get Free Repo

Provident Financial Services, Inc. Schedules Third Quarter Earnings Conference Call
globenewswire.com
Provident Financial Services, Inc. Schedules Third Quarter Earnings Conference Call

ISELIN, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Provident Financial Services, Inc. (NYSE: PFS) annou

Provident Bank Survey: 7 in 10 Americans Are Rethinking Higher Education, and Nearly 1 in 3 Are Eyeing the Alternatives
globenewswire.com
Provident Bank Survey: 7 in 10 Americans Are Rethinking Higher Education, and Nearly 1 in 3 Are Eyei

ISELIN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Provident Bank , a leading New Jersey-based financi

Provident Bank Goes Live with MANTL Business and Retail Account Opening Across its 135-Branch Network
prnewswire.com
Provident Bank Goes Live with MANTL Business and Retail Account Opening Across its 135-Branch Networ

More than 800 team members at the $25B+ bank have adopted MANTL to drive growth, efficiency, and bet

Koryx Copper Completes PFS Drill Program, Announces Further Positive Infill Drill Results at the Haib Copper Project in Southern Namibia
globenewswire.com
Koryx Copper Completes PFS Drill Program, Announces Further Positive Infill Drill Results at the Hai

Highlights  Assay results reported for 18 drill holes at Haib comprising 7,074m of infill and expans

RPX Gold Expands Gold Mineralization Beyond the PEA Open Pit and Underground Mine in Support of the Planned PFS
businesswire.com
RPX Gold Expands Gold Mineralization Beyond the PEA Open Pit and Underground Mine in Support of the

TORONTO--(BUSINESS WIRE)---- $RPX.V #Canada--RPX Gold Inc. (“RPX Gold” or the “Company”) (TSXV: RPX)

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
gurufocus.com
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median

Johnson and Johnson's RYBREVANTÂ (amivantamab-vmjw) plus chemotherapy delivers longest reported medi

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTIN
gurufocus.com
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 m

Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo's ENH

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
gurufocus.com
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZI

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM)

REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
gurufocus.com
REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses H

REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses H

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu
gurufocus.com
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Com

Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. [url="]announced[/ur

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
gurufocus.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Ph

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Ph

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
prnewswire.com
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Ph

First OX40 agonist to demonstrate clinical benefit in a randomized study INBRX-106 plus pembrolizuma

Wallbridge Reports Results from 2026 Fenelon PFS Metallurgical Drilling Program
globenewswire.com
Wallbridge Reports Results from 2026 Fenelon PFS Metallurgical Drilling Program

TORONTO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Wallbridge Mining Company Limited (TSX: WM, OTCQB: WLBMF

Provident Financial (PFS) Upgraded to Buy: Here's Why
zacks.com
Provident Financial (PFS) Upgraded to Buy: Here's Why

Provident Financial (PFS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism ab

Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline
gurufocus.com
Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagen

Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagen

Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
gurufocus.com
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lan

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results

benzinga.com
Keefe, Bruyette & Woods Reiterates Outperform on Provident Finl Servs, Raises Price Target to $28

Keefe, Bruyette & Woods analyst Timothy Switzer reiterates Provident Finl Servs (NYSE:PFS) wi

benzinga.com
Piper Sandler Reiterates Overweight on Provident Finl Servs, Raises Price Target to $29

Piper Sandler analyst Manuel Navas reiterates Provident Finl Servs (NYSE:PFS) with a Overweight a

benzinga.com
Provident Finl Servs Q2 EPS $0.60 Beats $0.56 Estimate, Sales $202.680M Miss $206.371M Estimate

Provident Finl Servs (NYSE:PFS) reported quarterly earnings of $0.60 per share which beat the analys

benzinga.com
Raymond James Maintains Strong Buy on Provident Finl Servs, Raises Price Target to $27

Raymond James analyst Steve Moss maintains Provident Finl Servs (NYSE:PFS) with a Strong Buy and

benzinga.com
Provident Financial Services Appoints Adriano Duarte CFO, Effective July 1

Provident Bank, a leading New Jersey-based financial institution, announced today the appointment of

benzinga.com
Stephens & Co. Initiates Coverage On Provident Finl Servs with Equal-Weight Rating, Announces Price

Stephens & Co. analyst Matt Breese initiates coverage on Provident Finl Servs (NYSE:PFS) with

benzinga.com
Keefe, Bruyette & Woods Maintains Outperform on Provident Finl Servs, Raises Price Target to $26

Keefe, Bruyette & Woods analyst Timothy Switzer maintains Provident Finl Servs (NYSE:PFS) wit

Full Transcript: Provident Finl Servs Q1 2026 Earnings Call
benzinga.com
Full Transcript: Provident Finl Servs Q1 2026 Earnings Call

benzinga.com
Provident Finl Servs Q1 EPS $0.61 Beats $0.55 Estimate, Sales $225.196M Beat $208.384M Estimate

Provident Finl Servs (NYSE:PFS) reported quarterly earnings of $0.61 per share which beat the analys

Earnings Scheduled For April 29, 2026
benzinga.com
Earnings Scheduled For April 29, 2026

benzinga.com
DA Davidson Initiates Coverage On Provident Finl Servs with Neutral Rating, Announces Price Target o

DA Davidson analyst Jake Civiello initiates coverage on Provident Finl Servs (NYSE:PFS) with a Ne

benzinga.com
Keefe, Bruyette & Woods Maintains Outperform on Provident Finl Servs, Raises Price Target to $25

Keefe, Bruyette & Woods analyst Timothy Switzer maintains Provident Finl Servs (NYSE:PFS) wit

benzinga.com
Provident Finl Servs Q4 EPS $0.64 Beats $0.56 Estimate, Sales $197.411M Miss $207.587M Estimate

Provident Finl Servs (NYSE:PFS) reported quarterly earnings of $0.64 per share which beat the analys

Earnings Scheduled For January 27, 2026
benzinga.com
Earnings Scheduled For January 27, 2026

Earnings Volatility Watch: These 10 Stocks Could Swing 30% Or More This Week
benzinga.com
Earnings Volatility Watch: These 10 Stocks Could Swing 30% Or More This Week

Options markets are pricing in post-earnings swings of up to 50% this week, with regional banks in f

A Look Ahead: Provident Finl Servs's Earnings Forecast
benzinga.com
A Look Ahead: Provident Finl Servs's Earnings Forecast

benzinga.com
Provident Financial Services CFO Thomas M. Lyons Intends To Retire On June 30

Provident Bank, a leading New Jersey-based financial institution, announced today the planned retire

benzinga.com
Provident Finl Servs Q3 EPS $0.55 Beats $0.54 Estimate, Sales $194.332M Miss $198.946M Estimate

Provident Finl Servs (NYSE:PFS) reported quarterly earnings of $0.55 per share which beat the analys

Earnings Scheduled For October 29, 2025
benzinga.com
Earnings Scheduled For October 29, 2025

benzinga.com
Provident Finl Servs's Earnings Outlook

benzinga.com
Provident Finl Servs Q2 EPS $0.55 Beats $0.50 Estimate, Net interest income $187.094M Miss $192.300M

Provident Finl Servs (NYSE:PFS) reported quarterly earnings of $0.55 per share which beat the analys

benzinga.com
Earnings Scheduled For July 24, 2025

benzinga.com
Raymond James Initiates Coverage On Provident Finl Servs with Strong Buy Rating, Announces Price Tar

Raymond James analyst Steve Moss initiates coverage on Provident Finl Servs (NYSE:PFS) with a Str

benzinga.com
Keefe, Bruyette & Woods Maintains Outperform on Provident Finl Servs, Lowers Price Target to $22

Keefe, Bruyette & Woods analyst Timothy Switzer maintains Provident Finl Servs (NYSE:PFS) wit

benzinga.com
Provident Finl Servs Q1 EPS $0.49 Beats $0.47 Estimate

Provident Finl Servs (NYSE:PFS) reported quarterly earnings of $0.49 per share which beat the analys

benzinga.com
Earnings Scheduled For April 24, 2025

benzinga.com
RBC Capital Maintains Outperform on Provident Finl Servs, Lowers Price Target to $23

RBC Capital analyst Jon Arfstrom maintains Provident Finl Servs (NYSE:PFS) with a Outperform and

benzinga.com
Provident Finl Servs Q4 2024 GAAP EPS $0.37 Misses $0.47 Estimate, Sales $181.74M Miss $184.78M Esti

Provident Finl Servs (NYSE:PFS) reported quarterly earnings of $0.37 per share which missed the anal

benzinga.com
Earnings Scheduled For January 28, 2025

benzinga.com
Hovde Group Initiates Coverage On Provident Finl Servs with Outperform Rating, Announces Price Targe

Hovde Group analyst Feddie Strickland initiates coverage on Provident Finl Servs (NYSE:PFS) with